JPWO2021076991A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2021076991A5
JPWO2021076991A5 JP2022522586A JP2022522586A JPWO2021076991A5 JP WO2021076991 A5 JPWO2021076991 A5 JP WO2021076991A5 JP 2022522586 A JP2022522586 A JP 2022522586A JP 2022522586 A JP2022522586 A JP 2022522586A JP WO2021076991 A5 JPWO2021076991 A5 JP WO2021076991A5
Authority
JP
Japan
Prior art keywords
antibody
composition
seq
amino acid
decreased
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022522586A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022551751A (ja
JP2022551751A5 (https=
JP7809056B2 (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/056121 external-priority patent/WO2021076991A1/en
Publication of JP2022551751A publication Critical patent/JP2022551751A/ja
Publication of JP2022551751A5 publication Critical patent/JP2022551751A5/ja
Publication of JPWO2021076991A5 publication Critical patent/JPWO2021076991A5/ja
Priority to JP2025171716A priority Critical patent/JP2026028257A/ja
Application granted granted Critical
Publication of JP7809056B2 publication Critical patent/JP7809056B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022522586A 2019-10-17 2020-10-16 血液障害を処置するための組成物及び方法 Active JP7809056B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025171716A JP2026028257A (ja) 2019-10-17 2025-10-10 血液障害を処置するための組成物及び方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962916492P 2019-10-17 2019-10-17
US62/916,492 2019-10-17
PCT/US2020/056121 WO2021076991A1 (en) 2019-10-17 2020-10-16 Compositions and methods for treating blood disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025171716A Division JP2026028257A (ja) 2019-10-17 2025-10-10 血液障害を処置するための組成物及び方法

Publications (4)

Publication Number Publication Date
JP2022551751A JP2022551751A (ja) 2022-12-13
JP2022551751A5 JP2022551751A5 (https=) 2023-10-24
JPWO2021076991A5 true JPWO2021076991A5 (https=) 2023-10-24
JP7809056B2 JP7809056B2 (ja) 2026-01-30

Family

ID=75538375

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022522586A Active JP7809056B2 (ja) 2019-10-17 2020-10-16 血液障害を処置するための組成物及び方法
JP2025171716A Pending JP2026028257A (ja) 2019-10-17 2025-10-10 血液障害を処置するための組成物及び方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025171716A Pending JP2026028257A (ja) 2019-10-17 2025-10-10 血液障害を処置するための組成物及び方法

Country Status (11)

Country Link
US (1) US20240109957A1 (https=)
EP (1) EP4045084A4 (https=)
JP (2) JP7809056B2 (https=)
KR (1) KR20220083737A (https=)
CN (1) CN114746118A (https=)
AU (1) AU2020365132A1 (https=)
BR (1) BR112022007051A2 (https=)
CA (1) CA3157873A1 (https=)
IL (1) IL292186A (https=)
MX (1) MX2022004287A (https=)
WO (1) WO2021076991A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015006507A1 (en) 2013-07-09 2015-01-15 Annexon, Inc. Methods of treatment for alzheimer's disease and huntington's disease
CA3195798A1 (en) * 2020-10-16 2022-04-21 Ted Yednock Compositions and methods for treating blood disorders
WO2023114763A1 (en) * 2021-12-13 2023-06-22 Annexon, Inc. Anti-complement factor c1q antibodies with single binding arms and uses thereof
CN118259018B (zh) * 2024-03-21 2024-10-29 泰州市人民医院 C1s抗体制备及其在ITP诊断中的应用
CN119371528B (zh) * 2024-10-30 2025-06-24 泰州市人民医院 一种C1q抗体及其应用、一种抑制补体经典途径活化的药剂及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009258063B2 (en) * 2007-06-21 2014-09-25 Macrogenics, Inc. BCR-complex-specific antibodies and methods of using same
KR101615935B1 (ko) * 2007-12-14 2016-04-28 노보 노르디스크 에이/에스 인간 ｎｋｇ2ｄ에 대한 항체 및 그것의 용도
BR112014013205A2 (pt) * 2011-12-01 2020-10-27 Protevobio, Inc. proteína de fusão, seu uso e seu método de produção, composição farmacêutica, ácido nucleico, e kit
KR102339315B1 (ko) * 2012-06-18 2021-12-15 오메로스 코포레이션 다양한 질환 및 장애의 치료를 위해 masp-1 및/또는 masp-2 및/또는 masp-3를 억제하는 조성물 및 방법
WO2015006507A1 (en) * 2013-07-09 2015-01-15 Annexon, Inc. Methods of treatment for alzheimer's disease and huntington's disease
CN104231085B (zh) * 2013-09-05 2017-03-15 复旦大学附属肿瘤医院 靶向特异性补体系统抑制剂、其制备方法及应用
HUE070383T2 (hu) * 2014-11-05 2025-06-28 Annexon Inc Humanizált C1Q anti-komplement faktor antitestek és alkalmazásaik
US9382321B2 (en) * 2014-11-26 2016-07-05 Adventis Health System/Sunbelt, Inc. Effector-deficient anti-CD32A antibodies
WO2017091719A1 (en) * 2015-11-24 2017-06-01 Annexon, Inc. Anti-complement factor c1q fab fragments and uses thereof

Similar Documents

Publication Publication Date Title
JP7141865B2 (ja) Ｃ５関連疾患の治療または予防用の医薬組成物およびｃ５関連疾患を治療または予防するための方法
JP6244350B2 (ja) ヒト化およびキメラ抗因子Ｂｂ抗体、ならびにその使用
JP2018520139A (ja) エクリズマブまたはエクリズマブバリアントでのワクチン接種に従って患者を処置するための方法
US20180171030A1 (en) Sirp-alpha agonist antibody
JP6672533B1 (ja) Ｃ５関連疾患の治療または予防用の医薬組成物およびｃ５関連疾患を治療または予防するための方法
JP2020511469A5 (https=)
CN1938047A (zh) 治疗溶血性疾病的方法
JP2019513726A5 (https=)
US11760810B2 (en) Modified immunoglobulin hinge regions to reduce hemagglutination
CN111868083A (zh) 因子h增强抗体及其用途
JPWO2021076991A5 (https=)
JP2021178857A (ja) Ｈ因子を強化する抗体及びその用途
JPWO2022081997A5 (https=)
JPWO2020154626A5 (https=)
CN114828886A (zh) 因子h增强抗体及其用途
JP2023526051A (ja) 発作性夜間ヘモグロビン尿症の処置のための補体ｄ因子阻害剤の単独又は抗ｃ５抗体との組み合わせでの使用
JP7735545B2 (ja) Ｃｄｃプラットホーム抗体
WO2025045251A2 (en) Multispecific constructs comprising anti-factor d moiety
EP4565611A1 (en) Anti- il27r antibodies and methods of use thereof
KR20250077505A (ko) 항-c1q 항체를 위한 제형
HK40109959A (zh) 使用激活素受体ii型信号传导抑制剂的方法
TH1801007665A (th) แอนติ-c5 แอนติบอดี และการใช้สิ่งนี้